Our results showed that temozolomide abrogated NRBF2 overexpression-induced antidepressant-like and proneurogenic effects in CSDS-exposed mice (Supplementary Fig. S5b–d), providing evidence that AHN is a crucial target of NRBF2-mediated regulation of depression-like behavior. The gene discussed is NRBF2; the disease is depressive symptom measurement.